ESMO 2017 Prostate Cancer

Viewing 1-20 of 41 articles

ESMO 2017: 14 years of progress in mCRPC – New avenues for immunotherapy and precision medicine: Invited Discussant

ESMO 2017: Prostate Cancer Poster Discussion: Invited Discussant

ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide

ESMO 2017: Cabazitaxel followed by ADT improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A Randomized, Open Label, Phase III, Multicenter trial

ESMO 2017: Assessment of health-related quality of life in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 vs 25 mg/m2 in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC)

ESMO 2017: Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

ESMO 2017: Management of M0 Patient with Rising PSA: How can PET imaging help?

ESMO 2017: The M0 Patient with Rising PSA - Case Presentation: The clinical problem, a multi-disciplinary issue

ESMO 2017: A Phase II Clinical Trial of Radium-223 Activity in Patients with mCRPC with Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status (EXCAAPE)

ESMO 2017: Immune Checkpoint Inhibitors in Prostate Cancer

ESMO 2017: Therapeutic Vaccines in Prostate Cancer

ESMO 2017: Immunogenomics of Lethal Prostate Cancer

ESMO 2017: Basic immunobiology in Prostate Cancer

ESMO 2017: Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: results from the CABADOC randomized trial

ESMO 2017: Adding abiraterone for patients with high-risk prostate cancer (PCa) starting long-term ADT: Outcomes in non-metastatic (M0) patients from STAMPEDE

ESMO 2017: What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis

ESMO 2017: PRORADIUM: Prospective Multi-Centre Study of Prognostic Factors in Castration Resistant Prostate Cancer Patients Treated with Radium-223

ESMO 2017: First Interim Results of the Radium-223 REASSURE Observational Study: Analysis of Patient Characteristics and Safety by Use of Abiraterone and/or Enzalutamide

ESMO 2017: Outcomes of Prechemotherapy Abiraterone Acetate or Enzalutamide for mCRPC after ADT + Docetaxel or ADT alone for mHSPC

ESMO 2017: Indirect Comparison of Abiraterone Acetate and Docetaxel for Treatment of Metastatic “Hormone-Sensitive” Prostate Cancer

1
2
3